CPA4 is a promising diagnostic serum biomarker for pancreatic cancer.
CPA4 is a promising diagnostic serum biomarker for pancreatic cancer.
复制标题
DOI：
--
复制
发表时间：
2016
影响因子：
5.3
通讯作者：
Li-chao Sun;Joseph P. Burnett;Chunguang Guo;Yibin Xie;Jian Pan;Zhihua Yang;Y. Ran;Duxin Sun
中科院分区：
文献类型：
--
作者：
Li-chao Sun;Joseph P. Burnett;Chunguang Guo;Yibin Xie;Jian Pan;Zhihua Yang;Y. Ran;Duxin Sun
CPA4属于金属羧肽酶家族的一员，其在胰腺癌样本中的表达及临床意义尚不明确。在本研究中，我们旨在评估胰腺癌样本中CPA4的水平，并研究其作为胰腺癌诊断标志物的临床意义。采用免疫组化（IHC）和酶联免疫吸附法（ELISA）分别检测胰腺癌组织和血清中CPA4的水平。在150例胰腺癌组织中，86.7%（130/150）的病例显示CPA4阳性染色。临床病理相关性分析显示CPA4表达与临床分期及淋巴结转移相关。此外，我们发现血清样本中CPA4的表达水平在配对组织样本中也很高的病例中显著高（N=50）。在更大的样本集中，我们发现胰腺癌患者血清CPA4显著高于健康对照组（P<0.05）。此外，高血清CPA4与TNM分期、淋巴结受累和远处转移显著相关。在0.3 ng/ml的临界值下，CPA4可能是比CA199更好的胰腺癌诊断生物标志物。综上所述，CPA4过表达与胰腺癌进展相关，可能是胰腺癌的潜在诊断血清标志物。
CPA4 belongs to a member of the metallocarboxypeptidase family, and its expression in pancreatic cancer samples and clinical significance are still not investigated until now. In this study, we aimed to evaluate the level of CPA4 in pancreatic cancer samples and study its clinical implications as a diagnostic marker for pancreatic cancer. The levels of CPA4 in pancreatic cancer tissues and serum samples were measured by immunohistochemistry (IHC) and enzyme-linked immunosorbent assay (ELISA), respectively. Among 150 pancreatic cancer tissues examined, 86.7% (130/150) of cases showed positive staining for CPA4. Clinicopathological relevance analysis showed that CPA4 expression was correlated with advanced clinical stage and lymph node metastasis. Also, we found that the levels of CPA4 in serum samples were significantly high in cases whose expression was also high in paired tissue samples (N=50). In a larger sample set, we found that serum CPA4 in pancreatic cancer patients was significantly higher than for healthy controls (P<0.05). In addition, high serum CPA4 was significantly associated with the TNM stage, Lymph node involvement and distant metastasis. At a cutoff value of 0.3 ng/ml, CPA4 might be a better diagnostic biomarker of pancreatic cancer than CA199. In conclusion, CPA4 overexpression is associated with pancreatic cancer progression, and it might be a potential diagnostic serum marker for pancreatic cancer.